A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

Completed · Not applicable

Conditions studied: Intestinal FDG Uptake

In brief

Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG) that is taken-up by active cells such as cancer cells. This contrast can then be seen in the body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can produce "false positive" signals from the colon. Our hypothesis is that much of this signal comes from bacteria that are present in high concentrations in the colon. If this is the case, using an antibiotic to suppress the activity of bacteria may improve the ability of PET-CT to distinguish abnormal cells from normal cells in the colon.

Key facts

Study ID

NCT01542541

Run by

Beth Israel Deaconess Medical Center

People needed

68

Starts

2011-07-01

Expected to finish

2012-10-01

Last updated by the study team

2017-12-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients undergoing clinically-indicated PET-CT scan for non-GI lymphoma

You may not qualify if…

• Patients with known Inflammatory Bowel Disease
• Patients with known colon cancer

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.